{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:54:01Z","timestamp":1787003641790,"version":"build-2736575974"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T00:00:00Z","timestamp":1665014400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T00:00:00Z","timestamp":1665014400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Dementia have substantial negative impact on the affected individual, their care partners and society. Persons living with Parkinson\u2019s disease (PwP) are also to a large extent living with dementia. The aim of this study is to estimate time to dementia in PD using data from a large quality register with access to baseline clinical and patient reported data merged with Swedish national health registries. Persons with Parkinson\u2019s disease in the Swedish Neuro Registries\/Parkinson\u2019s Disease Swedish PD Registry (PARKreg) in Sweden were included and linked to national health registries and matched by sex and age to controls without PD. Time to dementia was analysed with Cox regression models assuming proportional hazards, with time since diagnosis as the underlying time variable. In this large prospective cohort study, PwP had approximately four times higher risk of developing dementia as compared to age and sex-matched controls, a finding which remained after adjusting for potential confounders. The present results underline the high risk of dementia in PD and further emphasize the importance of developing symptomatic and ultimately disease modifying strategies to counteract this part of the non-motor symptomatology in PD.<\/jats:p>","DOI":"10.1038\/s41598-022-21093-8","type":"journal-article","created":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T12:04:42Z","timestamp":1665057882000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["High risk of developing dementia in Parkinson\u2019s disease: a Swedish registry-based study"],"prefix":"10.1038","volume":"12","author":[{"given":"Daniel Oudin","family":"\u00c5str\u00f6m","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Simonsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars Lau","family":"Raket","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Sgarbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Hellsten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Hagell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny M.","family":"Norlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klas","family":"Kellerborg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Martinez-Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Odin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,6]]},"reference":[{"key":"21093_CR1","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jalz.2012.11.007","volume":"9","author":"M Prince","year":"2013","unstructured":"Prince, M. et al. The global prevalence of dementia: A systematic review and metaanalysis. Alzheimer\u2019s Dementia 9, 63-75e62 (2013).","journal-title":"Alzheimer's Dementia"},{"key":"21093_CR2","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1017\/S1041610207005765","volume":"19","author":"ME De Boer","year":"2007","unstructured":"De Boer, M. E. et al. Suffering from dementia\u2014The patient\u2019s perspective: A review of the literature. Int. Psychogeriatr. 19, 1021\u20131039 (2007).","journal-title":"Int. Psychogeriatr."},{"key":"21093_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jad.2011.05.055","volume":"139","author":"R Li","year":"2012","unstructured":"Li, R., Cooper, C., Bradley, J., Shulman, A. & Livingston, G. Coping strategies and psychological morbidity in family carers of people with dementia: A systematic review and meta-analysis. J. Affect. Disord. 139, 1\u201311 (2012).","journal-title":"J. Affect. Disord."},{"key":"21093_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13195-016-0215-9","volume":"8","author":"A Wimo","year":"2016","unstructured":"Wimo, A. et al. The societal costs of dementia in Sweden 2012\u2014Relevance and methodological challenges in valuing informal care. Alzheimer\u2019s Res. Ther. 8, 1\u201311 (2016).","journal-title":"Alzheimer's Res. Ther."},{"key":"21093_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jalz.2012.11.006","volume":"9","author":"A Wimo","year":"2013","unstructured":"Wimo, A. et al. The worldwide economic impact of dementia 2010. Alzheimer\u2019s Dementia 9, 1-11e13 (2013).","journal-title":"Alzheimer's Dementia"},{"key":"21093_CR6","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1017\/S0033291700014665","volume":"21","author":"KP Ebmeier","year":"1991","unstructured":"Ebmeier, K. P. et al. Dementia in idiopathic Parkinson\u2019s disease: Prevalence and relationship with symptoms and signs of Parkinsonism. Psychol. Med. 21, 69\u201376 (1991).","journal-title":"Psychol. Med."},{"key":"21093_CR7","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1001\/archneur.1992.00530290076015","volume":"49","author":"R Mayeux","year":"1992","unstructured":"Mayeux, R. et al. A population-based investigation of Parkinson\u2019s disease with and without dementia: Relationship to age and gender. Arch. Neurol. 49, 492\u2013497 (1992).","journal-title":"Arch. Neurol."},{"key":"21093_CR8","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1001\/archneur.1996.00550060082020","volume":"53","author":"D Aarsland","year":"1996","unstructured":"Aarsland, D., Tandberg, E., Larsen, J. P. & Cummings, J. L. Frequency of dementia in Parkinson disease. Arch. Neurol. 53, 538\u2013542 (1996).","journal-title":"Arch. Neurol."},{"key":"21093_CR9","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jns.2009.08.034","volume":"289","author":"D Aarsland","year":"2010","unstructured":"Aarsland, D. & Kurz, M. W. The epidemiology of dementia associated with Parkinson disease. J. Neurol. Sci. 289, 18\u201322 (2010).","journal-title":"J. Neurol. Sci."},{"key":"21093_CR10","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1002\/mds.20527","volume":"20","author":"D Aarsland","year":"2005","unstructured":"Aarsland, D., Zaccai, J. & Brayne, C. A systematic review of prevalence studies of dementia in Parkinson\u2019s disease. Mov. Disord. 20, 1255\u20131263 (2005).","journal-title":"Mov. Disord."},{"key":"21093_CR11","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.jns.2017.01.012","volume":"374","author":"HA Hanagasi","year":"2017","unstructured":"Hanagasi, H. A., Tufekcioglu, Z. & Emre, M. Dementia in Parkinson\u2019s disease. J. Neurol. Sci. 374, 26\u201331 (2017).","journal-title":"J. Neurol. Sci."},{"key":"21093_CR12","doi-asserted-by":"publisher","first-page":"fcac040","DOI":"10.1093\/braincomms\/fcac040","volume":"4","author":"D B\u00e4ckstr\u00f6m","year":"2022","unstructured":"B\u00e4ckstr\u00f6m, D. et al. Prediction and early biomarkers of cognitive decline in Parkinson disease and atypical parkinsonism: A population-based study. Brain Commun. 4, fcac040 (2022).","journal-title":"Brain Commun."},{"key":"21093_CR13","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1002\/acn3.51022","volume":"7","author":"D Weintraub","year":"2020","unstructured":"Weintraub, D. et al. Neuropsychiatric symptoms and cognitive abilities over the initial quinquennium of Parkinson disease. Ann. Clin. Transl. Neurol. 7, 449\u2013461 (2020).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"21093_CR14","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1016\/S0140-6736(15)00462-6","volume":"386","author":"Z Walker","year":"2015","unstructured":"Walker, Z., Possin, K. L., Boeve, B. F. & Aarsland, D. Lewy body dementias. Lancet 386, 1683\u20131697 (2015).","journal-title":"Lancet"},{"key":"21093_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0175560","volume":"12","author":"I Huertas","year":"2017","unstructured":"Huertas, I. et al. Genetic factors influencing frontostriatal dysfunction and the development of dementia in Parkinson\u2019s disease. PLoS ONE 12, e0175560 (2017).","journal-title":"PLoS ONE"},{"key":"21093_CR16","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1212\/WNL.0000000000000842","volume":"83","author":"JB Anang","year":"2014","unstructured":"Anang, J. B. et al. Predictors of dementia in Parkinson disease: A prospective cohort study. Neurology 83, 1253\u20131260 (2014).","journal-title":"Neurology"},{"key":"21093_CR17","doi-asserted-by":"publisher","first-page":"159","DOI":"10.3233\/JPD-160925","volume":"7","author":"J Anang","year":"2017","unstructured":"Anang, J. et al. Dementia predictors in Parkinson disease: A validation study. J. Parkinsons Dis. 7, 159\u2013162 (2017).","journal-title":"J. Parkinsons Dis."},{"key":"21093_CR18","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1016\/j.parkreldis.2014.06.006","volume":"20","author":"K Zhu","year":"2014","unstructured":"Zhu, K., van Hilten, J. J. & Marinus, J. Predictors of dementia in Parkinson\u2019s disease; findings from a 5-year prospective study using the SCOPA-COG. Parkinsonism Relat. Disord. 20, 980\u2013985 (2014).","journal-title":"Parkinsonism Relat. Disord."},{"key":"21093_CR19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3233\/JPD-209003","volume":"10","author":"W Gryc","year":"2020","unstructured":"Gryc, W. et al. Hallucinations and development of dementia in Parkinson\u2019s disease. J. Parkinson\u2019s Dis. 10, 1\u20136 (2020).","journal-title":"J. Parkinson's Dis."},{"key":"21093_CR20","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1002\/mds.22843","volume":"24","author":"K Dujardin","year":"2009","unstructured":"Dujardin, K., Sockeel, P., Delliaux, M., Dest\u00e9e, A. & Defebvre, L. Apathy may herald cognitive decline and dementia in Parkinson\u2019s disease. Mov. Disord. 24, 2391\u20132397 (2009).","journal-title":"Mov. Disord."},{"key":"21093_CR21","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1017\/cjn.2017.239","volume":"45","author":"MW Hussain","year":"2018","unstructured":"Hussain, M. W. & Camicioli, R. Nonmotor symptoms of Parkinson\u2019s disease as predictors of dementia. Can. J. Neurol. Sci. 45, 97\u201399 (2018).","journal-title":"Can. J. Neurol. Sci."},{"key":"21093_CR22","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1017\/S1355617720001216","volume":"27","author":"I Galtier","year":"2021","unstructured":"Galtier, I., Nieto, A., Mata, M., Lorenzo, J. N. & Barroso, J. Analyses of visuospatial and visuoperceptual errors as predictors of dementia in Parkinson\u2019s disease patients with subjective cognitive decline and mild cognitive impairment. J. Int. Neuropsychol. Soc. 27, 722\u2013732 (2021).","journal-title":"J. Int. Neuropsychol. Soc."},{"key":"21093_CR23","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/S1474-4422(19)30024-9","volume":"18","author":"L Parnetti","year":"2019","unstructured":"Parnetti, L. et al. CSF and blood biomarkers for Parkinson\u2019s disease. Lancet Neurol. 18, 573\u2013586 (2019).","journal-title":"Lancet Neurol."},{"key":"21093_CR24","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.1016\/j.parkreldis.2017.07.023","volume":"46","author":"LV Kalia","year":"2018","unstructured":"Kalia, L. V. Biomarkers for cognitive dysfunction in Parkinson\u2019s disease. Parkinsonism Relat. Disord. 46, S19\u2013S23 (2018).","journal-title":"Parkinsonism Relat. Disord."},{"key":"21093_CR25","doi-asserted-by":"publisher","first-page":"391","DOI":"10.3389\/fneur.2019.00391","volume":"10","author":"TR Melzer","year":"2019","unstructured":"Melzer, T. R. et al. Beta amyloid deposition is not associated with cognitive impairment in Parkinson\u2019s disease. Front. Neurol. 10, 391 (2019).","journal-title":"Front. Neurol."},{"key":"21093_CR26","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1136\/jnnp-2014-307659","volume":"86","author":"H-F Wang","year":"2015","unstructured":"Wang, H.-F. et al. Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson\u2019s disease, Parkinson\u2019s disease dementia, and dementia with Lewy bodies: Systematic review with meta-analysis and trial sequential analysis. J. Neurol. Neurosurg. Psychiatry 86, 135\u2013143 (2015).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"21093_CR27","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1002\/mds.20213","volume":"19","author":"CG Goetz","year":"2004","unstructured":"Goetz, C. G. et al. Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: Status and recommendations the Movement Disorder Society Task Force on rating scales for Parkinson\u2019s disease. Mov. Disord. 19, 1020\u20131028 (2004).","journal-title":"Mov. Disord."},{"key":"21093_CR28","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1136\/bmj.326.7382.219","volume":"326","author":"DG Altman","year":"2003","unstructured":"Altman, D. G. & Bland, J. M. Interaction revisited: The difference between two estimates. BMJ 326, 219 (2003).","journal-title":"BMJ"},{"key":"21093_CR29","doi-asserted-by":"publisher","first-page":"268","DOI":"10.7326\/M16-2607","volume":"167","author":"TJ VanderWeele","year":"2017","unstructured":"VanderWeele, T. J. & Ding, P. Sensitivity analysis in observational research: Introducing the E-value. Ann. Intern. Med. 167, 268\u2013274 (2017).","journal-title":"Ann. Intern. Med."},{"key":"21093_CR30","unstructured":"Kassambara, A. K., & Marcin, B. Przemyslaw Survminer: Drawing Survival Curves Using 'ggplot2'. (2020)."},{"key":"21093_CR31","doi-asserted-by":"publisher","first-page":"2965","DOI":"10.2147\/NDT.S304567","volume":"17","author":"MD Smith","year":"2021","unstructured":"Smith, M. D., Brazier, D. E. & Henderson, E. J. Current perspectives on the assessment and management of gait disorders in Parkinson\u2019s disease. Neuropsychiatr. Dis. Treat. 17, 2965 (2021).","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"21093_CR32","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1007\/s40266-016-0416-8","volume":"33","author":"N Samudra","year":"2016","unstructured":"Samudra, N., Patel, N., Womack, K. B., Khemani, P. & Chitnis, S. Psychosis in Parkinson disease: A review of etiology, phenomenology, and management. Drugs Aging 33, 855\u2013863 (2016).","journal-title":"Drugs Aging"},{"key":"21093_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-021-04356-8","volume":"12","author":"LL Raket","year":"2022","unstructured":"Raket, L. L. et al. Impact of age at onset on symptom profiles, treatment characteristics and health-related quality of life in Parkinson\u2019s disease. Sci. Rep. 12, 1\u201313 (2022).","journal-title":"Sci. Rep."},{"key":"21093_CR34","first-page":"4","volume":"8","author":"DJ Irwin","year":"2018","unstructured":"Irwin, D. J. & Hurtig, H. I. The contribution of tau, amyloid-beta and alpha-synuclein pathology to dementia in Lewy body disorders. J. Alzheimer\u2019s Dis. Parkinson. 8, 4 (2018).","journal-title":"J. Alzheimer's Dis. Parkinson."},{"key":"21093_CR35","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1111\/ane.13502","volume":"144","author":"F Hjalte","year":"2021","unstructured":"Hjalte, F., Norlin, J. M., Kellerborg, K. & Odin, P. Parkinson\u2019s disease in Sweden\u2014Resource use and costs by severity. Acta Neurol. Scand. 144, 592\u2013599 (2021).","journal-title":"Acta Neurol. Scand."},{"key":"21093_CR36","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.jamda.2020.06.025","volume":"22","author":"A Hosking","year":"2021","unstructured":"Hosking, A. et al. Characteristics of patients with late-stage Parkinsonism who are nursing home residents compared with those living at home. J. Am. Med. Dir. Assoc. 22, 440\u2013445 (2021).","journal-title":"J. Am. Med. Dir. Assoc."},{"key":"21093_CR37","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.3390\/life11111239","volume":"11","author":"T-S Fan","year":"2021","unstructured":"Fan, T.-S., Liu, S.C.-H. & Wu, R.-M. Alpha-synuclein and cognitive decline in Parkinson disease. Life 11, 1239 (2021).","journal-title":"Life"},{"key":"21093_CR38","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1002\/mds.26191","volume":"30","author":"M Petrou","year":"2015","unstructured":"Petrou, M. et al. Amyloid deposition in Parkinson\u2019s disease and cognitive impairment: A systematic review. Mov. Disord. 30, 928\u2013935 (2015).","journal-title":"Mov. Disord."},{"key":"21093_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2458-11-450","volume":"11","author":"JF Ludvigsson","year":"2011","unstructured":"Ludvigsson, J. F. et al. External review and validation of the Swedish national inpatient register. BMC Public Health 11, 1\u201316 (2011).","journal-title":"BMC Public Health"},{"key":"21093_CR40","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1212\/01.WNL.0000134604.48018.97","volume":"63","author":"Y-P Jin","year":"2004","unstructured":"Jin, Y.-P., Gatz, M., Johansson, B. & Pedersen, N. L. Sensitivity and specificity of dementia coding in two Swedish disease registries. Neurology 63, 739\u2013741 (2004).","journal-title":"Neurology"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-21093-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-21093-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-21093-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T23:26:57Z","timestamp":1665098817000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-21093-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,6]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["21093"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-21093-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,6]]},"assertion":[{"value":"16 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16759"}}